



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of
FRACCO ET AL.

RECEIVED

Examiner: **MCKELVEY, T.**

Serial No.: **08/930,480**

JUN 11 2001

Art Unit: **1636**

TECH CENTER 1600/2900

Filed: **JANUARY 21, 1998**

I hereby certify that this correspondence is being deposited with the United States Postal Service as regular mail in an envelope addressed to Commissioner for Patents, Washington, D.C. 20231, on

June 1, 2001

Date of Deposit

Signature

STATEMENT REGARDING CONTENT OF PAPER AND COMPUTER READABLE COPIES PURSUANT TO 37 C.F.R. 1.821 (f)

Commissioner for Patents

Washington, D.C. 20231

Sir:

The undersigned states that the content of the nucleotide and/or amino acid sequences set forth in the enclosed substitute pages of the "Sequence Listing" and the computer readable copies required by 37 C.F.R. 1.821 (e) submitted herewith are the same; and (2) the content of the substitute copy of the Sequence Listing and the computer readable copies required by 37 C.F.R. 1.821 (e) contain no new matter. Support for the Amendments can be found in the application as filed.

Respectfully submitted,

William C. Coppola, Reg. No. 41,686
Attorney/Agent for Applicant

Aventis Pharmaceuticals Inc.
Patent Department
Route #202-206 / P.O. Box 6800
Bridgewater, New Jersey 08807-0800
Telephone (908) 231-4854
Telefax (908) 231-2626

Docket No. ST95021-US